FDA issues guidance on Premarket Approval (PMA) and Humanitarian Device Exemption (HDE) supplements during COVID-19

2024-02-26T09:10:23+00:00May 25th, 2020|Categories: Clinical Trial, Compliance, Covid-19, USA|Tags: , , , , |

The US Food and Drug Administration (FDA) issued a guidance with immediate effect which allows medical device manufacturers to make “limited modifications” to their devices without submitting a premarket approval (PMA), humanitarian device exemption (HDE) supplement or a 30-day [...]

The European Commission simplifies the process for renewing notified body designations

2024-02-29T14:38:43+00:00May 22nd, 2020|Categories: Compliance, Covid-19, Europe, MDR, Regulatory|Tags: , , , , |

The European Commission issued new regulations simplifying  the process for renewing notified body designations prior to the postponed deadline for application of the Medical Devices Regulations (MDR), 26 May 2021. Moreover, the Commission issued guidelines explaining the process and requirements [...]

UK: Managing clinical trials during COVID-19

2024-02-29T15:17:32+00:00May 22nd, 2020|Categories: Clinical Trial, Covid-19, Europe, Regulatory, UK|Tags: , , , , , |

On 21 May 2020, NIHR set out a framework to guide the restarting of NIHR research activities which have been paused due to COVID-19. Sponsors planning to restart trials or to initiate new clinical trials should take account of the principles [...]

Germany: BfArM and PEI issued supplementary recommendations on management of clinical trials during COVID-19 pandemic

2024-02-26T11:08:52+00:00May 22nd, 2020|Categories: Clinical Trial, Covid-19, Europe, Regulatory|Tags: , , , , , |

BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) and PEI (Paul-Ehrlich-Institut) provided supplementary recommendations to the guideline on management of clinical trials during COVID-19 released by the European authorities on 20th March 2020. Key points of BfArM and PEI recommendations on [...]

UK: MHRA updates regulatory status of equipment being used to help prevent coronavirus (COVID-19)

2024-02-29T16:29:24+00:00May 20th, 2020|Categories: Compliance, Covid-19, UK|Tags: , , , |

MHRA issued update to regulations which apply to devices and equipment including hand gels and PPE (personal protective equipment). Contents Antimicrobial hand sanitisers and gels Face masks Gloves Offers to supply or donate healthcare equipment to the NHS/healthcare providers [...]

EMA: Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19

2024-02-02T11:50:42+00:00May 19th, 2020|Categories: Covid-19, Europe, Regulatory|Tags: , , , |

The International Coalition of Medicines Regulatory Authorities (ICMRA) convened a virtual meeting of regulators from around the world on 14 May 2020 to discuss high-level policy issues and regulatory requirements to respond to the ongoing COVID-19 pandemic. The strategic [...]

AUSTRIA: BASG issues information on the withdrawal of measures for clinical trials at the end of the pandemic

2024-02-01T15:08:04+00:00May 19th, 2020|Categories: Clinical Trial, Covid-19, Europe|Tags: , , , |

The Austrian Federal Office for Safety in Health Care (BASG) updated its FAQ with new information related to the communication with the Federal Office and the withdrawal of measures at the end of the COVID-19 pandemic. Communication with the [...]

FDA issued a Guidance on Conduct of Clinical Trials of Medical Products during COVID-19

2024-02-07T16:16:06+00:00May 18th, 2020|Categories: Clinical Trial, Covid-19, Regulatory, USA|Tags: , , , , |

FDA issued a guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 emergency. FDA [...]

EMA updates its governance during COVID-19 pandemic

2024-02-02T11:48:58+00:00May 14th, 2020|Categories: Compliance, Covid-19, Europe, Regulatory|Tags: , , , |

The European Medicines Agency (EMA) updated information on its dedicated task forces to deal with the scientific, regulatory and operational challenges generated by the COVID-19 pandemic and initiated its business continuity plan. The aim of these measures is to [...]

Go to Top